Related Experiment Videos
Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
Jassim Al Suwaidi1, Amar M Salam
1Department of Cardiology and Cardiovascular Surgery, Hamad Medical Corporation, Doha, State of Qatar. jha01@hmc.org.qa
Current Controlled Trials in Cardiovascular Medicine
|January 25, 2002
Abstract:
Glycoprotein IIb/IIIa inhibitors represent a new promising class of antiplatelet medications. Their use in acute coronary syndromes and for patients undergoing percutaneous coronary intervention has been the subject of a number of large controlled trials using both the intravenous and the oral forms. In this review, we present a systematic overview of these trials.